Simplify your path to TPD success. Download our brochure.

Untangling targeted protein degrader (TPD) clinical development

Targeted protein degraders (TPDs) offer great promise in treating some of the most challenging diseases. But clinical development is fraught with complex biomarker challenges.

To succeed, you must deeply understand your TPD’s mechanisms of action, accurately monitor target degradation to optimize dosing, and unveil the causes of resistance — which is no easy feat.

Download our brochure today and find out how, with deep TPD expertise and a comprehensive multi-omics approach, we can steer you through the complexities of understanding TPD potency, dose optimization, and resistance mechanisms, helping you increase your chances of TPD clinical development success.

Download the resource

As a global research organization, we prioritize your study goals and clinical trial needs above all else. We aim to provide you with easy, accessible, and comprehensive technologies spanning a multitude of therapeutic areas. Discover our range of services in immunology, histopathology, proteomics, genomics, as well as related ML/AI and sample logistics services.

Simplify your path to TPD success. Download our brochure.

Untangling targeted protein degrader (TPD) clinical development

Targeted protein degraders (TPDs) offer great promise in treating some of the most challenging diseases. But clinical development is fraught with complex biomarker challenges.

To succeed, you must deeply understand your TPD’s mechanisms of action, accurately monitor target degradation to optimize dosing, and unveil the causes of resistance — which is no easy feat.

Download our brochure today and find out how, with deep TPD expertise and a comprehensive multi-omics approach, we can steer you through the complexities of understanding TPD potency, dose optimization, and resistance mechanisms, helping you increase your chances of TPD clinical development success.

Download the resource

As a global research organization, we prioritize your study goals and clinical trial needs above all else. We aim to provide you with easy, accessible, and comprehensive technologies spanning a multitude of therapeutic areas. Discover our range of services in immunology, histopathology, proteomics, genomics, as well as related ML/AI and sample logistics services.

Immuno-MRM Assays

August 4, 2023

DOWNLOAD OUR BROCHURE

CellCarta’s immuno-MRM assays, based on immunoaffinity enrichment of peptides coupled to liquid chromatography-targeted multiple reaction monitoring (LC-MRM), allow for sensitive and precise protein quantification. We offer nine CPTAC validated panels to investigate DNA damage response (DDR1, 2, 3), immuno-oncology (IO-1, 2, 3), Ras-MAPK signaling pathway (Ras-MAPK1, 2), and human epidermal growth factor receptor 2 (HER2) expression. Our team continually develops new panels, combining up to 50 targets (listed below), for your specific needs. With CAP-accredited and CLIA-certified sites, we provide the highest standard of quality.

Contact us for any custom development.

Immuno-MRM

Immuno-MRM Assays

August 4, 2023

DOWNLOAD OUR BROCHURE

CellCarta’s immuno-MRM assays, based on immunoaffinity enrichment of peptides coupled to liquid chromatography-targeted multiple reaction monitoring (LC-MRM), allow for sensitive and precise protein quantification. We offer nine CPTAC validated panels to investigate DNA damage response (DDR1, 2, 3), immuno-oncology (IO-1, 2, 3), Ras-MAPK signaling pathway (Ras-MAPK1, 2), and human epidermal growth factor receptor 2 (HER2) expression. Our team continually develops new panels, combining up to 50 targets (listed below), for your specific needs. With CAP-accredited and CLIA-certified sites, we provide the highest standard of quality.

Contact us for any custom development.

Immuno-MRM

CellCarta - Mapping Precision Medicine

July 26, 2023

DOWNLOAD OUR CORPORATE BROCHURE

CellCarta-Cover

 

CellCarta - Mapping Precision Medicine

July 26, 2023

DOWNLOAD OUR CORPORATE BROCHURE

CellCarta-Cover

 

Wondering if the assay you use during your clinical trial is subject to IVD legislation ?

April 13, 2023

DOWNLOAD OUR INFOGRAPHIC

Wondering if the assay you use during your clinical trial is subject to IVD legislation ?

Wondering if the assay you use during your clinical trial is subject to IVD legislation ?

April 13, 2023

DOWNLOAD OUR INFOGRAPHIC

Wondering if the assay you use during your clinical trial is subject to IVD legislation ?

Next-Generation Flow Cytometry Analysis with CellEngine™

January 31, 2023

DOWNLOAD OUR INFOGRAPHIC

Next-Generation Flow Cytometry Analysis with CellEngine™

January 31, 2023

DOWNLOAD OUR INFOGRAPHIC